Biomarkers Development

The development of cancer therapies is increasingly dependent on our understanding of tumor biology, and biomarkers—especially predictive biomarkers—are crucial tools in the field of personalized medicine and health economics, in particular, as they enable definition of the populations of patients who are most likely to benefit from targeted therapies. More-effective patient selection than is possible at present is mandatory to improve the success rate of new therapies, which are sometimes prohibitively expensive, and thereby increase their cost–utility; thus, delineating reliable predictive biomarkers is essential if we are to achieve this objective. One commonly used definition of a biomarker is a measurable indicator that is used to distinguish precisely, reproducibly and objectively either a normal biological state from a pathological state, or the response to a specific therapeutic intervention. In fact, biomarkers are used for numerous purposes: to predict survival (prognostic biomarkers); to assess drug safety and evaluate target engagement and the immediate consequence on biological processes (pharmacodynamics biomarkers), to identify patients who are more likely to benefit from a treatment (predictive biomarkers; more generally termed companion biomarkers when associated with a specific therapeutic agent); to predict outcome given the response to therapy (surrogate biomarkers); and to monitor disease progression or therapeutic efficacy (monitoring biomarkers). Identification and widespread use of biomarkers will help ensure that patients receive the best possible therapeutic strategies, thereby avoiding unnecessary treatments and associated toxicities, and eventually reducing total health costs.

Even though immunotherapeutic approaches are being studied in many cancer types, correlative studies have thus far been most extensively conducted in melanoma, providing valuable experience and making it a model system for identifying therapeutic biomarkers.

  • Turning an Active Compound into a Personalized Medicine
  • Evaluation of Biomarker Performance in the Real World
  • Predicting Benefit to Therapy: Biomarkers and Molecular Profiles in Oncology Drug Development
  • Identification of Fluid Biomarkers of Treatment
  • Surrogate endpoints: utilising biomarkers in clinical trials

Related Conference of Biomarkers Development

September 01-02, 2017

4th International Conference on Parasitology

Prague, Czech Republic
September 11-12, 2017

7th World Congress on Immunology

Amsterdam, Netherlands
November 2-3, 2017

9th World Congress and Expo on Immunology

Atlanta, Georgia, USA
November 02-03, 2017

9th World Congress on Immunity, Inflammation and Immunotherapies

Atlanta, Georgia, USA
November 06-07, 2017

2nd International Conference on Autoimmunity

Frankfurt, Germany
November 08-09, 2017

3rd Antibodies and Bio Therapeutics Congress & B2B

Las Vegas, Nevada, USA
November 13-14, 2017

5th International Conference on HIV/AIDS, STDs and STIs

Las Vegas, Nevada, USA
Dec 14-15, 2017

World Immunology Congress

Dubai, UAE

9th European Immunology Conference

June 14-16, 2018 Rome, Italy
July 05-07, 2018

EuroSciCon Conference on Immunology

Vienna, Austria

Biomarkers Development Conference Speakers

Recommended Sessions

Related Journals

Are you interested in